Organon & Co. (NYSE:OGN – Get Free Report) has earned a consensus rating of “Reduce” from the seven research firms that are covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation and five have given a hold recommendation to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $11.40.
OGN has been the subject of several recent research reports. Piper Sandler upgraded shares of Organon & Co. from an “underweight” rating to a “neutral” rating and boosted their price target for the company from $5.00 to $14.00 in a report on Tuesday, April 28th. BNP Paribas Exane reiterated a “neutral” rating and set a $14.00 price objective (up from $12.00) on shares of Organon & Co. in a research note on Wednesday, April 29th. Weiss Ratings raised shares of Organon & Co. from a “sell (d+)” rating to a “hold (c-)” rating in a report on Friday, May 15th. Finally, Zacks Research raised shares of Organon & Co. from a “strong sell” rating to a “hold” rating in a research note on Tuesday, April 14th.
Read Our Latest Research Report on Organon & Co.
Insider Buying and Selling at Organon & Co.
Hedge Funds Weigh In On Organon & Co.
Large investors have recently made changes to their positions in the business. Cetera Investment Advisers boosted its stake in Organon & Co. by 1.7% in the 1st quarter. Cetera Investment Advisers now owns 48,073 shares of the company’s stock worth $288,000 after purchasing an additional 788 shares during the period. State of Alaska Department of Revenue grew its stake in Organon & Co. by 0.6% during the 4th quarter. State of Alaska Department of Revenue now owns 278,379 shares of the company’s stock valued at $1,995,000 after acquiring an additional 1,570 shares in the last quarter. Integrated Wealth Concepts LLC increased its holdings in shares of Organon & Co. by 2.8% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 58,648 shares of the company’s stock valued at $626,000 after purchasing an additional 1,594 shares during the period. Rafferty Asset Management LLC lifted its position in shares of Organon & Co. by 8.5% in the second quarter. Rafferty Asset Management LLC now owns 23,578 shares of the company’s stock worth $228,000 after purchasing an additional 1,847 shares in the last quarter. Finally, Bank of Nova Scotia lifted its position in shares of Organon & Co. by 4.6% in the third quarter. Bank of Nova Scotia now owns 44,512 shares of the company’s stock worth $475,000 after purchasing an additional 1,947 shares in the last quarter. 77.43% of the stock is owned by institutional investors and hedge funds.
Organon & Co. Stock Up 0.1%
Shares of Organon & Co. stock traded up $0.01 during trading on Friday, hitting $13.56. 1,508,001 shares of the stock traded hands, compared to its average volume of 2,268,647. The company has a current ratio of 1.97, a quick ratio of 1.42 and a debt-to-equity ratio of 9.47. The stock’s fifty day simple moving average is $13.27 and its 200 day simple moving average is $9.53. The firm has a market cap of $3.56 billion, a P/E ratio of 14.59, a price-to-earnings-growth ratio of 1.25 and a beta of 1.54. Organon & Co. has a 52-week low of $5.69 and a 52-week high of $13.60.
Organon & Co. (NYSE:OGN – Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The company reported $0.71 earnings per share for the quarter, missing analysts’ consensus estimates of $0.83 by ($0.12). Organon & Co. had a return on equity of 99.95% and a net margin of 3.99%.The business had revenue of $1.46 billion during the quarter, compared to analysts’ expectations of $1.49 billion. During the same period last year, the company earned $1.02 earnings per share. The firm’s revenue was down 3.5% compared to the same quarter last year. On average, equities analysts predict that Organon & Co. will post 3.23 earnings per share for the current fiscal year.
Organon & Co. Dividend Announcement
The business also recently declared a quarterly dividend, which was paid on Thursday, June 11th. Stockholders of record on Monday, May 11th were given a $0.02 dividend. This represents a $0.08 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend was Monday, May 11th. Organon & Co.’s payout ratio is presently 8.60%.
Organon & Co. Company Profile
Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.
In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.
Read More
- Five stocks we like better than Organon & Co.
- Why Microsoft Looks Like the Best Big Tech Trade for H2 2026
- Strategy’s Bitcoin Pivot Gives Investors a New Reason to Watch Preferred Shares
- 2 AI Stocks That Could Benefit as AI Moves Beyond the Data Center
- These Stocks Could Win as Wall Street Looks Beyond AI Software
Receive News & Ratings for Organon & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organon & Co. and related companies with MarketBeat.com's FREE daily email newsletter.
